What is Sixfold Bioscience?
Sixfold Bioscience is a venture-backed, preclinical-stage biotechnology company headquartered at the Innovation and Translation Hub in White City, London. The company is dedicated to the development of innovative nucleic acid-based drug delivery systems. Its current strategic focus is on advancing Cell & Gene therapeutics, particularly utilizing short interfering RNA (siRNA) for gene silencing and messenger RNA (mRNA) for gene expression. This focus positions Sixfold at the forefront of next-generation therapeutic modalities.
How much funding has Sixfold Bioscience raised?
Sixfold Bioscience has raised a total of $10.5M across 1 funding round:
Angel/Seed
$10.5M
Angel/Seed (2021): $10.5M with participation from Pi Campus, Lombardstreet Ventures, Y Combinator, and Cantos Ventures
Key Investors in Sixfold Bioscience
Pi Campus
Pi Campus is a venture capital firm and startup district based in Rome, focusing on early-stage startups, particularly those applying artificial intelligence to solve significant challenges in traditional industries. They provide funding and mentorship to foster entrepreneurial growth.
Lombardstreet Ventures
Lombardstreet Ventures is a pre-seed venture capital firm investing in early-stage US companies, with a focus on B2B Software, SaaS Applications, Developer Tools, and AI. They actively support entrepreneurs in nurturing the next wave of tech leaders.
Y Combinator
Y Combinator, established in 2005, is a renowned startup accelerator based in Mountain View, California, providing seed funding and mentorship to early-stage businesses.
What's next for Sixfold Bioscience?
The recent major strategic investment in Sixfold Bioscience signals a critical growth phase for the company, likely enabling it to advance its preclinical drug candidates through key development milestones. This capital infusion is expected to accelerate research and development efforts, potentially leading to the initiation of clinical trials and further validation of its proprietary drug delivery platforms. The company's focus on siRNA and mRNA technologies aligns with significant trends in the biopharmaceutical industry, suggesting a strong market appetite for its innovative solutions.
See full Sixfold Bioscience company page
